GleamWall
中文EN

NNVC NANOVIRICIDES, INC.

Pharmaceutical Preparations · NYSE · SEC CIK 1379006 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.9%
TTM EPS YoY-8.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-179.2%
ROA-135.9%
ROIC (approx.)-196.2%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets33.5%
Debt / equity0.00x
Current ratio0.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-27.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$0$0
R&D expense$4.71M$5.55M
SG&A expense$3.60M$4.04M
Operating income-$8.31M-$9.59M
Interest expense—$149
Pretax income-$8.22M—
Net income-$8.22M-$9.47M
EBITDA-$7.79M-$8.86M
EPS (basic)-0.41-0.63
EPS (diluted)-0.41-0.63
Weighted avg. shares (diluted)20.19M15.12M
Balance sheet
Cash & equivalents$2.79M$1.56M
Current assets$3.16M$1.67M
PP&E, net$6.40M$6.83M
Intangibles$308,769$317,039
Total assets$9.87M$8.82M
Current liabilities$1.19M$1.31M
Total liabilities$1.20M$1.30M
Shareholders' equity$8.68M$7.52M
Shares outstanding23.01M16.61M
Cash flow statement
Operating cash flow-$7.70M-$8.48M
Capital expenditure$84,317$56,964
Free cash flow-$7.78M-$8.54M
Investing cash flow-$84,317-$56,964
Financing cash flow$9.02M$5.30M
Depreciation & amortization$517,016$735,536

Free plan shows the latest 2 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.